Akums Q1 FY25 revenue up 5.1%
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
The JV will establish a state-of-the-art manufacturing facility to manufacture fermented animal free protein to cater to the global markets
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
Coveris’ security labels also work seamlessly with self-checkouts where around 80% of retail sales now typically occur
This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
This project is supported by the Irish Government through IDA Ireland
Subscribe To Our Newsletter & Stay Updated